Evaluation of cardiotoxicity and other adverse effects associated with concomitant administration of artemether/lumefantrine and atazanavir/ritonavir-based antiretroviral regimen in patients living with HIV

• Main Authors: Sikiru Olatunji Usman (Author), Ibrahim Adekunle Oreagba (Author), AbdulWasiu Busari (Author), Akinwumi Akinyede (Author), Ololade Adewumi (Author), Michael Rotimi Kadri (Author), Olayinka Hassan (Author), Yinka Adeyemi Fashina (Author), Esther Oluwatoyin Agbaje (Author), Sulaimon Alani Akanmu (Author)
• Format: Book
• Published: Elsevier, 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The interplay of artemether-lumefantrine (AL) and atazanavir-ritonavir (ATVr) with Cytochrome P (CYP) 3A4 isoenzyme and QTc-interval may spawn clinically significant drug interactions when administered concomitantly. Cardiotoxicity and other adverse effects associated with interaction between AL and...